Renovaro Inc. Files 8-K with Corporate Updates
Ticker: LNAI · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financials, amendment
TL;DR
Renovaro Inc. filed an 8-K on 8/26/25 for corporate updates and financials.
AI Summary
Renovaro Inc. filed an 8-K on August 26, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits. The company, formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc., is incorporated in Delaware and has its fiscal year end on June 30.
Why It Matters
This filing indicates corporate housekeeping and the submission of financial information, which is crucial for investors to assess the company's financial health and operational status.
Risk Assessment
Risk Level: low — The filing is routine and pertains to corporate structure and financial reporting, not indicating immediate operational or financial distress.
Key Numbers
- 001-38751 — Commission File Number (Identifies the company's filing with the SEC)
- 45-2259340 — I.R.S. Employer Identification Number (Tax identification for the company)
Key Players & Entities
- RENOVARO INC. (company) — Registrant
- Enochian Biosciences Inc. (company) — Former company name
- Renovaro Biosciences Inc. (company) — Former company name
- August 26, 2025 (date) — Date of earliest event reported
FAQ
What specific amendments were made to Renovaro Inc.'s articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt. The full filing would contain this information.
What financial statements and exhibits were filed with this 8-K?
The filing states that 'Financial Statements and Exhibits' were filed, but the specific content of these documents is not detailed in the provided excerpt.
When was Renovaro Inc. previously known as Enochian Biosciences Inc. and Renovaro Biosciences Inc.?
The filing indicates name changes occurred on August 7, 2023 (from Enochian Biosciences Inc. to Renovaro Biosciences Inc.) and August 2, 2023 (from Renovaro Biosciences Inc. to Renovaro Inc.).
What is Renovaro Inc.'s fiscal year end?
Renovaro Inc.'s fiscal year end is June 30.
Where is Renovaro Inc. incorporated?
Renovaro Inc. is incorporated in Delaware.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-26 16:45:53
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
Filing Documents
- e6800_8k.htm (8-K) — 27KB
- e6800_ex3-1.htm (EX-3.1) — 9KB
- image_007.gif (GRAPHIC) — 1KB
- 0001731122-25-001173.txt ( ) — 202KB
- renb-20250826.xsd (EX-101.SCH) — 3KB
- renb-20250826_lab.xml (EX-101.LAB) — 33KB
- renb-20250826_pre.xml (EX-101.PRE) — 22KB
- e6800_8k_htm.xml (XML) — 4KB
03. Amendments
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 18, 2025, Renovaro Inc. (the "Company") filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to change its corporate name from "Renovaro Inc." to "Lunai Bioworks Inc." (the "Name Change"). The Name Change became effective on August 20, 2025. The Company's common stock will continue to trade on the Nasdaq under the ticker symbol RENB, although the CUSIP number for the common stock will be changed as a result of the Name Change. A copy of the Certificate of Amendment as filed with the Secretary of State of the State of Delaware is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Restated Certificate of Incorporation of Renovaro Inc., dated August 18, 2025 (Name Change)
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking standards. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's control, and actual results may differ materially from those described in such statements. Readers are cautioned not to place undue reliance on these forward-looking statements.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ David Weinstein Name: David Weinstein Title: Chief Executive Officer Date: August 26, 2025